NCT06254599 2024-02-12A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCShouyao Holdings (Beijing) Co. LTDPhase 3 Not yet recruiting255 enrolled